ESR1 and breast cancer: While recent genomic studies have provided a comprehensive catalog of genes that accumulate somatic point mutations and small insertions/deletions (indels) in estrogen receptor-positive (ER+) breast cancer, there remains considerable uncertainty as to how these newly discovered mutations relate to disease outcomes1–3.